Data from Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia

作者：Alak Manna, Sonikpreet Aulakh, Prachi Jani, Salman Ahmed, Sharoon Akhtar, Marie Coignet, Michael Heckman, Zahara Meghji, Kirtipal Bhatia, Aarushi Sharma, Taimur Sher, Victoria Alegria, Fabio Malavasi, Eduardo N. Chini, Asher Chanan-Khan, Sikander Ailawadhi, Aneel Paulus · 年份：2026 · DOI：10.1158/1078-0432.c.8542687 · 研究领域：Chronic Lymphocytic Leukemia Research、Calcium signaling and nucleotide metabolism、Phagocytosis and Immune Regulation

<div>AbstractPurpose:CD38 has emerged as a high-impact therapeutic target in multiple myeloma, with the approval of daratumumab (anti-CD38 mAb). The clinical importance of CD38 in patients with chronic lymphocytic leukemia (CLL) has been known for over 2 decades, although it's relevance as a therapeutic target in CLL remains understudied.Experimental Design:We investigated the biological effects and antitumor mechanisms engaged by daratumumab in primary CLL cells. Besides its known immune-effector mechanisms (antibody-dependent cell-mediated cytotoxicity, complement-dependent death, and antibody-dependent cellular phagocytosis), we also measured direct apoptotic effects of daratumumab alone or in combination with ibrutinib. In vivo antileukemic activity was assessed in a partially humanized xenograft model. The influence of CD38 on B-cell receptor (BCR) signaling was measured via immunoblotting of Lyn, Syk, BTK, PLCγ2, ERK1/2, and AKT.Results:In addition to immune-effector mechanisms; daratumumab also induced direct apoptosis of primary CLL cells, which was partially dependent on FcγR cross-linking. For the first time, we demonstrated the influence of CD38 on BCR signaling where interference of CD38 downregulated Syk, BTK, PLCγ2, ERK1/2, and AKT; effects that were further enhanced by addition of ibrutinib. In comparison to single-agent treatment, the combination of ibrutinib and daratumumab resulted in si...